Evidence record · ER-BPC157-TENDON-001
Does BPC-157 heal tendons and ligaments?
BPC-157 heals injured tendons and ligaments in people
BPC-157 has not been shown to heal tendons or ligaments in dependable human trials. Laboratory and animal findings support a research hypothesis, but the available clinical literature is too sparse to estimate benefit, compare it with rehabilitation or surgery, or establish a human safety profile.
Claim boundary
What this verdict covers
The claim concerns clinically meaningful recovery after a diagnosed tendon or ligament injury, not a cell response, collagen marker or appearance of repaired tissue in an animal model.
- Compound
- BPC-157
- Population
- People with tendon or ligament injury
- Outcome
- Tendon or ligament healing
- Record ID
- ER-BPC157-TENDON-001
Evidence synthesis
What the research can support
A 2025 systematic review found that almost all orthopaedic BPC-157 research was preclinical. One small retrospective human report did not provide a controlled basis for tendon or ligament healing. Animal findings cannot supply the size, timing or durability of a human treatment effect.
Why the confidence is very low
No suitable randomised human trial, validated functional outcome, credible comparator or dependable adverse-event programme was identified. Online-product identity is a separate untested question.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-BPC157-TENDON-001 addresses one bounded question: Does BPC-157 heal tendons and ligaments?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Preclinical only, the verdict is Insufficient and confidence is Very low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| 2025 systematic review of BPC-157 in orthopaedic sports medicine | The review found 35 preclinical studies and one small retrospective human report. | It cannot turn animal findings into a clinical healing estimate. | 10 August 2026 |
| FDA BPC-157 compounding review | FDA reviewed pharmacology, evidence and safety gaps for BPC-157. | A US compounding assessment does not test an individual UK vial. | 10 August 2026 |
| WADA 2026 Prohibited List | BPC-157 is prohibited at all times under S0. | The list is a sport rule, not evidence of clinical effectiveness. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on BPC-157 for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
A 2025 systematic review found that almost all orthopaedic BPC-157 research was preclinical. One small retrospective human report did not provide a controlled basis for tendon or ligament healing. Animal findings cannot supply the size, timing or durability of a human treatment effect. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is BPC-157 authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
BPC-157 is named on the 2026 WADA Prohibited List under non-approved substances and is prohibited at all times. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
A prospectively registered, independently run human trial using a characterised product, a credible comparator and patient-important function and reinjury outcomes. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation